Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MSD’s Molnupiravir Up for PAFSC Review on Dec. 24
A key Japanese health ministry panel will discuss whether to grant special approval for MSD’s oral COVID-19 drug molnupiravir at its meeting on December 24. If approved, it will be Japan’s first oral treatment for the disease. The Ministry of…
To read the full story
Related Article
- MSD Japan Boosts COVID-19 Pill Supply to 800,000 Courses by March
February 15, 2022
- Japan Receiving 90,000 Further Courses of MSD COVID-19 Pill Earlier than Scheduled
February 7, 2022
- MSD Moves Up Supply of 50000 Courses of Lagevrio to Japan
January 31, 2022
- Japan Approves MSD’s Oral COVID-19 Drug Molnupiravir
December 27, 2021
- MSD Files Oral COVID-19 Drug in Japan
December 3, 2021
- Japan to Receive 1.6 Million Courses of MSD’s COVID-19 Drug
November 11, 2021
REGULATORY
- Govt to Explore Greater Rewards for Innovative Drugs in Honebuto
June 29, 2026
- MHLW Starts Technical Review of OTC-Like Drug Charge Exemptions
June 29, 2026
- Takeda to Shift Immunoglobulin Production to 10% Formulation
June 29, 2026
- Japan’s Immunoglobulin Self-Sufficiency Rate Falls Below 60%
June 29, 2026
- MOF Panel Renews Push for Full-Scale Off-Year Revision in FY2027
June 29, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…